Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment

PURPOSE: Enzalutamide resistance could result from raised androgens and be overcome by combination with abiraterone acetate. PLATO (ClinicalTrials.gov identifier: NCT01995513) interrogated this hypothesis using a randomized, double-blind, placebo-controlled design. PATIENTS AND METHODS: In period on...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Attard, Gerhardt, Borre, Michael, Gurney, Howard, Loriot, Yohann, Andresen-Daniil, Corina, Kalleda, Ranjith, Pham, Trinh, Taplin, Mary-Ellen
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2018
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6118405/
https://ncbi.nlm.nih.gov/pubmed/30028657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2018.77.9827
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars